Neogenomics
NeoGenomics Q2 Revenues up 18 Percent as Firm Beats Analyst Estimates
The firm said that both its test volume and average revenue per test were up year over year, with 295,116 tests performed during the quarter.
Natera Sues NeoGenomics for Patent Infringement
Natera alleges that NeoGenomics is infringing on two patents related to the Signatera minimal residual disease testing platform.
NeoGenomics Gets Medicare Coverage for Radar Minimal Residual Disease Assay in Breast Cancer
The firm's tumor-informed, patient-personalized tests are now covered for residual disease detection and monitoring in breast cancer patients effective March 24.
In Brief This Week: Epigenomics, NeoGenomics, Agilent, OpGen, More
News items for the week of June 12, 2023.
Liquid Biopsy Firms Eye Melanoma for Minimal Residual Disease Testing, Though Questions Remain
Premium
MRD assays show promise in immunotherapy response prediction with the potential to guide dose/treatment escalation with emerging adjuvant approaches.
Feb 23, 2023
Feb 15, 2023
Dec 12, 2022
Nov 8, 2022
Aug 9, 2022
Apr 1, 2022
360Dx Top 30 Falls Slightly in March
Feb 17, 2022